Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Taiho Oncology, Inc

Home Clinical Trial Sponsors and OrganizationsTaiho Oncology, Inc

Taiho Oncology, Inc

101 Carnegie Ctr Ste 101, Princeton, New Jersey, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

8

8 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

8

100.0%

Trial Status Distribution

Active, not recruiting

8

100.0%

Clinical Trials

Trials sponsored by this organization (8)

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Jul 2016507 participants

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Apr 2016500 participants

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Dec 2015500 participants

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Dec 2015507 participants

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Nov 2015500 participants

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Nov 2015500 participants

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Nov 2015500 participants

This is clinical trial for a registration to investigate superiority of overall survival by TAS-102 plus best supportive care compared to placebo (an inactive drug) plus best supportive care in patients with metastatic gastric cancer who had refractory to standard therapies

Active, not recruiting

Sep 2015500 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials8
Approvals
News

Back to Organizations